Alternate sunitinib schedules in patients with metastatic renal cell carcinoma

被引：41

作者：

Kalra, S. ^{[1
]}

Rini, B. I. ^{[2
]}

Jonasch, E. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA

[2] Cleveland Clin, Taussig Canc Inst, Dept Solid Tumor Oncol, Cleveland, OH 44106 USA

来源：

ANNALS OF ONCOLOGY | 2015年 / 26卷 / 07期

关键词：

sunitinib; renal cell carcinoma; drug administration schedule; alternate schedule; PHASE-II TRIAL; INTERFERON-ALPHA; DOSING SCHEDULE; CANCER; TOXICITY; SURVIVAL; EFFICACY; OUTCOMES; THERAPY; REGIMEN;

D O I：

10.1093/annonc/mdv030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor exhibiting antiangiogenic activity. Sunitinib demonstrated improved outcomes in comparison to interferon- a in a large phase III study of treatment naive patients with metastatic renal cell carcinoma. Maintaining patients on sunitinib treatment is essential for a sustained disease control as higher exposure to sunitinib has been associated with an improved overall response rate, progression- free survival and overall survival. Various studies have compared the outcomes of patients undergoing sunitinib therapy based on modifications from their standard dose and schedule. Several studies have shown that switching to an alternate schedule with more frequent dose interruptions without affecting dose density over a 6- week cycle is associated with improved outcomes and increased tolerability.

引用

页码：1300 / 1304

页数：5

共 20 条

[1] Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules [J].

Atkinson, Bradley J. ;

Kalra, Sarathi ;

Wang, Xuemei ;

Bathala, Tharakeswara ;

Corn, Paul ;

Tannir, Nizar M. ;

Jonasch, Eric .

JOURNAL OF UROLOGY, 2014, 191 (03) :611-618

[2] Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma [J].

Barrios, Carlos H. ;

Hernandez-Barajas, David ;

Brown, Michael P. ;

Lee, Se-Hoon ;

Fein, Luis ;

Liu, Jin-Hwang ;

Hariharan, Subramanian ;

Martell, Bridget A. ;

Yuan, Jinyu ;

Bello, Akintunde ;

Wang, Zhixiao ;

Mundayat, Rajiv ;

Rha, Sun-Young .

CANCER, 2012, 118 (05) :1252-1259

[3] Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature [J].

Bjarnason, Georg A. ;

Khalil, Bishoy ;

Hudson, John M. ;

Williams, Ross ;

Milot, Laurent M. ;

Atri, Mostafa ;

Kiss, Alex ;

Burns, Peter N. .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (04) :480-487

[4] Sunitinib: From rational design to clinical efficacy [J].

Chow, Laura Q. M. ;

Eckhardt, S. Gail .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) :884-896

[5] Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma [J].

Escudier, Bernard ;

Roigas, Jan ;

Gillessen, Silke ;

Harmenberg, Ulrika ;

Srinivas, Sandhya ;

Mulder, Sasja F. ;

Fountzilas, George ;

Peschel, Christian ;

Flodgren, Per ;

Maneval, Edna Chow ;

Chen, Isan ;

Vogelzang, Nicholas J. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) :4068-4075

[6] Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer [J].

Faivre, S ;

Delbaldo, C ;

Vera, K ;

Robert, C ;

Lozahic, S ;

Lassau, N ;

Bello, C ;

Deprimo, S ;

Brega, A ;

Massimini, G ;

Armand, JP ;

Scigalla, P ;

Raymond, E .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) :25-35

[7] Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients [J].

Griffioen, Arjan W. ;

Mans, Laurie A. ;

de Graaf, Annemarie M. A. ;

Nowak-Sliwinska, Patrycja ;

de Hoog, Celine L. M. M. ;

de Jong, Trees A. M. ;

Vyth-Dreese, Florry A. ;

van Beijnum, Judy R. ;

Bex, Axel ;

Jonasch, Eric .

CLINICAL CANCER RESEARCH, 2012, 18 (14) :3961-3971

[8] Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis [J].

Houk, Brett E. ;

Bello, Carlo L. ;

Poland, Bill ;

Rosen, Lee S. ;

Demetri, George D. ;

Motzer, Robert J. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (02) :357-371

[9] Superior Tolerability of Altered Dosing Schedule of Sunitinib with 2-Weeks-on and 1-Week-off in Patients with Metastatic Renal Cell Carcinoma-Comparison to Standard Dosing Schedule of 4-Weeks-on and 2-Weeks-off [J].

Kondo, Tsunenori ;

Takagi, Toshio ;

Kobayashi, Hirohito ;

Iizuka, Junpei ;

Nozaki, Taiji ;

Hashimoto, Yasunobu ;

Ikezawa, Eri ;

Yoshida, Kazuhiko ;

Omae, Kenji ;

Tanabe, Kazunari .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (03) :270-277

[10]

Mittal Kriti, 2012, Biol Ther, V2, P5, DOI 10.1007/s13554-012-0005-2

← 1 2 →